PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson’s Disease

There is hardly any doubt that video content is increasingly becoming more popular among people who are looking to get information about a range of subjects. Hence, it is no surprise that YouTube is now littered with a range of channels on almost any subject one might think of and it is no different in the case of stock market investing.

Among the many stock market investment channels that have sprung up in recent times, RichTV Live has been one of the more popular ones. The channel published videos almost every day and is well known for providing reliable information to its subscribers. Yesterday, the RichTV host conducted a live stream in which he looked into the company PharmaTher Holdings Ltd (CSE:PHRM) (OTCQB:PHRRF). RichTV Live is well known for bringing under the radar companies to the attention of its investors and this was no different.

Enter Your E-mail Address To Subscribe

* indicates required

Key Details

On Monday, PharmaTher Holdings made a major announcement with regards to a key milestone. The company announced that the United States Food and Drug Administration approved the company’s application with regards to the Phase 2 clinical trial of its Investigational New Drug. It is a major development for the company and one that is likely to bring it into the radar of many investors in the coming days.

Hence, it did not come as a surprise that it had been picked up by Rich Tv. Over the past months, RichTV has provided such deep analysis of breaking news stories on a regular basis and investors are almost always provided with a complete picture about the whole thing.

The phase 2 clinical trial is going to be centered around the possibility of deploying pharmacokinetics, which are derived from ketamine, for treating levodopa-induced dyskinesia in patients with Parkinson’s disease. It is an ambitious project and could have far-reaching ramifications for PharmaTher and its long-term growth.

The Rich Tv host spoke at length about the possibilities of the trial and was also quite detailed in the thoroughness with which PharmaTher is going to approach the trial. It is now going to be interesting to see if the latest development leads to any kind of rally in the PharmaTher stock price or not.

Featured image: Pixabay

Please See Disclaimer

If You Liked This Article Click To Share

Risks and Disclosure:

Information provided in this correspondence is intended solely for informational purposes and is obtained from sources believed to be reliable. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained on this website is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions made or suggested and the actual results.

All statements and opinions expressed are the opinions of the author and not of or its officers. The author is wholly responsible for the validity of all statements. was not involved in any aspect of the article preparation. The author was not paid by Bitrex Inc for this article. The author did not pay to publish or syndicate this article.

This article does not constitute as investment advice. Each reader is encouraged to consult with his or her individual financial advisor; any and all actions taken by a reader as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to's terms of use and full legal disclaimer. This article is in no way a solicitation for investment. does not render general or specific investment advice. Any information on should not be considered a recommendation to buy or sell any security. does not endorse or recommend the business, products, services or securities of any company mentioned on

Futures, stocks and options trading involves substantial risk of loss and is not suitable for every investor. The valuation of futures, stocks, and options may fluctuate, and, as a result, clients may lose more than their original investment and possibly their entire investment. Any content on this website should not be relied upon as advice or construed as providing recommendations of any kind. It is your responsibility to confirm and decide which trades to make. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Please see our full disclaimer here for additional details before making any investment decisions.